New program pairs microdoses of GLP-1 medication with Noom’s powerful behavior-change program and at-home biomarker testing to track the health impact of combining GLP-1 therapy with healthy habits.

First publicly listed company to actively investigate psilocybin’s potential impact on longevity Working closely with an academic neuroscience faculty, Psyence BioMed is developing an accelerated ...

Company builds on earlier GLP-1 success with breakthrough AI-led insights into aging biology -- targeting the widely projected $60B longevity therapeutics market HYFT®-driven discovery supports ...

SCOTTSDALE, Ariz., Aug. 12, 2025 /PRNewswire/ -- Jocasta Neuroscience, Inc., a preclinical stage, longevity-focused company, with its lead asset, a proprietary ...

This week, Vail Health launches its new Healthspan program, designed to take a natural, science-based approach to improving quality of life and longevity. “Healthspan, at its core, is a lifestyle ...

First publicly listed company to actively investigate psilocybin’s potential impact on longevity NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or ...